Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display - Cocktail

302 - Rational Combinations of Active and Passive Immunotherapy Mobilize Immune and clinical responses in terminal cancers


24 Nov 2018


Poster display - Cocktail


Immunotherapy;  End-of-Life Care

Tumour Site


Runsheng Ruan


Annals of Oncology (2018) 29 (suppl_9): ix170-ix172. 10.1093/annonc/mdy433


R. Ruan1, Q.Z. Ruan2

Author affiliations

  • 1 Key Laboratory For Translational Cancer Immunotherapy, Xiamen University, 361102 - Xiamen/CN
  • 2 General Surgery, Staten Island University Hospital, 10301 - NY /US


Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 302


It is now recognized that solid tumours encroach on the host’s immune microenvironment to favour its own proliferation. Strategies to enhance the specificity of the endogenous T cell population against tumours have been met with limited clinical success. We aimed to devise a 2-tier protocol coupling in vivo whole antigen priming with ex vivo cellular expansion to clinically evaluate survival in patients following re-infusion of primed, autologous T cells, to determining treatment efficacy.


Cancer cell lysate was administered intradermally once a month for 3 months, followed by twice-weekly for 3 weeks infusion of autologous CD8+ lymphocyte expanded ex-vivo. Post treatment tumor-specific T cell response and cytotoxicity was confirmed and evaluated for associations with survival status and duration.


There was significant increase in cytotoxicity exhibited by T cells measured using both Elispot and RTCA following treatment. Correlation analysis determined significant association between higher post treatment cytotoxicity scores and survival status (R = 0.52, p = 0.0028) as well as longer survival duration in months (R = 0.59, p = 0.005).


Our treatment protocol successfully demonstrated significant correlation between tumor associated antigen specific immune response and objective prolongation of survival. Whole cell cancer antigen priming and adoptive T cell therapy is therefore a highly feasible clinical model which can be easily replicated to positively influence outcome in end-stage malignancy.

Editorial acknowledgement

Clinical trial identification

Legal entity responsible for the study

Key Laboratory for Translational Medicine of Cancer Theranostics, Xiamen, China.


Key Laboratory for Translational Medicine of Cancer Theranostics, Xiamen, China.


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.